Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | US

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Kidswell Bio Corporation Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.	Japan	4584
Kinarus Therapeutics Holding AG A specialty pharma firm developing and selling medicines for rare and specialty diseases.	Switzerland	KNRS
Kiniksa Pharmaceuticals International, plc Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.	United States of America	KNSA
KIORA PHARMACEUTICALS INC Developing advanced small molecule therapies for vision-threatening retinal diseases.	United States of America	KPRX
KISSEI PHARMACEUTICAL CO.,LTD. Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.	Japan	4547
Klaria Pharma Holding AB Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.	Sweden	KLAR
Klotho Neurosciences, Inc. Advancing gene and cell therapies for neurodegenerative disorders, cancer, and chronic diseases.	United States of America	KLTO
KOA SHOJI HOLDINGS CO.,LTD. Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.	Japan	9273
KOBAYASHI PHARMACEUTICAL CO.,LTD. Manufactures OTC pharma, personal care, and household goods for niche consumer markets.	Japan	4967
Kodiak Sciences Inc. Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.	United States of America	KOD